Anixa biosciences inc (ANIX)
CashFlow / Quarterly
Jan'20Oct'19Jul'19Apr'19Jan'19Oct'18Jul'18Apr'18Jan'18Oct'17Jul'17Apr'17Jan'17Oct'16Jul'16Apr'16Jan'16Oct'15Jul'15Apr'15Jan'15Oct'14Jul'14Apr'14Jan'14Oct'13Jul'13Apr'13Jan'13Oct'12Jul'12Apr'12Jan'12Oct'11Jul'11Apr'11Jan'11
Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18

-523

655

-55

-9

-956

152

-55

42

45

-60

69

63

72

436

42

-105

88

150

107

-198

-30

132

Royalties and contingent legal fees payable

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-194

-13

-5

-62

32

-22

-294

407

-330

436

-161

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-246

-246

-446

-

-

-

-

Cash flows from operating activities:
Net loss

-2,616

-2,111

-2,166

-2,574

-4,966

-5,391

-5,593

-1,392

-1,865

-1,785

-1,794

160

-1,589

-1,047

-1,103

-1,271

-1,593

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,292

-1,602

-2,236

3,752

-3,153

411

-3,249

-3,614

-2,926

-2,581

-2,476

-2,094

-1,860

-629

-877

-886

-2,791

-1,773

-1,287

-1,526

Stock option compensation to employees and directors

963

751

784

805

1,219

2,118

3,126

258

214

286

481

191

259

303

240

217

112

338

780

1,065

491

803

469

1,156

720

-

-

-

-

-

-

-

-

-

-

-

-

Stock options and warrants issued to consultants

57

59

46

46

46

64

127

73

52

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted stock award compensation to employee pursuant to stock incentive plan

-

0

0

470

1,484

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of interest on patent acquisition obligations to interest expense

-

-

-

-

-

-

-

-

-

456

0

-86

-141

-136

-132

-126

-123

-118

-115

-326

109

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued to consultants

-

-

-

-

-

-

-

-

-

-

-

0

17

3

16

5

6

0

40

2

4

43

5

6

28

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation of property and equipment

-

-

-

-

-

-

-

2

4

11

10

10

10

8

11

10

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-

-

-

-

Depreciation of property and equipment

14

-

-

-

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

1

Amortization of operating lease right-to-use asset, net of lease payments

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock option compensation to employees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

574

1,090

554

473

-

-

-

-

-

-

-

-

Stock option compensation to consultants

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued to consultants

-

-

-

-

-

0

0

0

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock option compensation to consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

241

-

-

-

-

-

-

-

-

Common stock issued to consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

-

-

-

-

-

-

-

-

Amortization of patents

-

0

41

125

251

81

81

81

81

81

81

81

81

81

81

81

81

81

81

81

81

81

81

81

70

0

0

0

0

-

-

-

-

-

-

-

-

Impairment in carrying amount of patent asset

-

0

0

0

418

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortized interest on patent acquisition obligations to interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of convertible debenture discount charge to interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

59

128

229

217

98

92

795

5

-

-

-

-

-

-

-

-

Accrued interest on secured debenture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

32

28

-

-

-

-

-

-

-

-

-

-

-

-

Change in value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

867

850

-990

-1,320

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of noncontrolling interest in Certainty Therapeutics, Inc. expensed as a license fee

-

-

-

-

-

0

0

0

64

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25

-

-

-

-

-

-

-

-

Common stock issued to acquire patent license

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Gain on sale of Digital Info Security Co., Inc. common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-60

26

4

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

-8

-6

-38

-0

-0

2

25

0

-1

-33

13

-6

0

-0

-

-

-

-

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

266

-695

828

-175

-

-

-

-

-

-

-

-

-

-

-

-

Receivables

-44

34

-795

693

-203

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-355

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-30

55

5

-106

55

-114

81

-22

103

-186

296

-3

-93

105

17

-16

-70

-67

151

-23

5

-40

-33

-7

-19

86

-4

-14

11

-

-

-

-

17

80

-20

-31

Accounts payable

-218

18

-150

104

30

162

-32

35

-63

14

17

-92

167

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-190

19

-2

163

31

-26

-178

218

260

-31

228

28

87

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-1,914

-1,337

-640

-1,434

-1,329

-1,020

-1,169

-742

-1,339

-739

-1,251

-1,076

-729

-682

-814

-1,351

-532

-801

-708

-1,779

4,653

-362

-337

-507

-1,172

-544

-839

-912

-890

-962

-628

-892

-657

-712

1,332

-726

-609

Cash flows from investing activities:
Disbursements to acquire short-term investments in certificates of deposit

1,870

-

-

-

-

250

2,750

0

1,250

1,250

2,001

2,250

0

0

350

1,300

250

350

150

1,750

650

1,500

1,000

0

2,700

-

-

-

-

0

200

750

250

-

-

-

-

Proceeds from maturities of short-term investments in certificates of deposit

1,350

1,250

2,000

0

250

1,000

1,250

1,400

2,100

2,001

0

600

150

1,150

600

1,300

500

350

150

2,000

500

1,550

500

400

250

250

0

0

500

449

799

1,249

449

-

-

-

-

Proceeds from sale of Digital Info Security Co. Inc. common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

95

22

Purchase of property and equipment

15

-

-

-

-

6

20

9

2

13

2

0

14

1

3

35

106

0

0

0

54

-

-

-

-

-

-

-

-

-

0

0

0

0

0

2

6

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

-1

1

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-535

-250

650

-1,175

250

743

-1,520

1,390

847

782

-2,003

-1,650

135

1,148

246

-35

143

0

0

250

-204

47

-502

398

-2,450

0

-1

1

498

450

599

499

199

749

-1,649

-1,255

16

Cash flows from financing activities:
Proceeds from issuance of convertible debentures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,500

0

0

0

1,765

-

-

-

-

-

-

-

-

Net proceeds from sale of common stock in at-the-market offering

1,751

627

541

2,204

2,153

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Redemption of convertible preferred stock

-

-

-

-

-

-

-

-

-

0

0

0

500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

28

19

22

57

22

-

-

-

-

1

0

0

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

61

147

185

521

99

477

Net cash provided by financing activities

1,780

681

564

2,279

2,176

-

-

-

-

1,462

2,211

4,203

-494

-

-

-

-

-

-

-

-

24

3,873

-49

3,500

460

549

471

1,765

750

0

61

147

185

521

1,349

477

Net (decrease) increase in cash and cash equivalents

-669

-

-

-

1,096

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

1,325

-492

1,505

-1,043

1,476

-1,088

439

-563

-1,368

-388

-791

-919

-1,729

4,448

-290

3,033

-158

-122

-83

-291

-439

1,373

238

-29

-332

-311

222

204

-631

-115

Supplemental disclosure of non-cash investing and financing activities:
Operating lease right-to-use asset

-106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability

106

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments to suppliers, employees and consultants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

964

646

2,213

-659

-713

-4,004

814

623

Cash received from sales of products and services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

2

0

27

88

13

Redemption of Series A convertible preferred stock into secured debenture (Note 5)

-

-

-

-

-

-

-

-

-

0

0

0

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of debenture embedded conversion feature, at issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,570

-

-

-

-

-

-

-

-

-

-

-

-

Relative fair value of convertible debenture warrant, at issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

513

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-1,914

-1,337

-640

-1,434

-1,329

-1,020

-1,169

-742

-1,339

-739

-1,251

-1,076

-729

-

-

-

-

-

-

-

-

-

-

-

-

-

-839

-912

-890

-962

-628

-892

-657

-712

1,332

-726

-609